

Supporting Information

Stable Triplex Formation Using the Strong Stacking Effect of Consecutive Thionucleoside Moieties Incorporated into Triplex-Forming Oligonucleotides

Akihiro Ohkubo, Yudai Nishino, Akira Yokouchi, Yu Ito, Yasuhiro Noma, Yoshiaki

Masaki, Hirosuke Tsunoda, Kohji Seio, and Mitsuo Sekine *


Department of Life Science, Tokyo Institute of Technology

Content

General Remarks-----	S3
Synthesis of compound 7-----	S3
Synthesis of phosphoramidite unit 1-----	S4
Synthesis of compound 11-----	S6
Synthesis of compound 12-----	S7
Synthesis of compound 13-----	S8
Synthesis of compound 14-----	S8
Synthesis of phosphoramidite unit 2-----	S9
Synthesis of phosphoramidite unit 3-----	S10
Synthesis of compound 17-----	S11
Synthesis of compound 18-----	S12
Synthesis of compound 19-----	S12
Synthesis of compound 20-----	S13
Synthesis of phosphoramidite unit 4-----	S13
Synthesis of compound 22-----	S15
Synthesis of phosphoramidite unit 5-----	S16

Synthesis of TFOs 2-12 and 15-17-----	S17
Table S1-----	S19
Figure S1-----	S20
Figure S2-----	S21
Figure S3-----	S22
Figure S4-----	S23
Figure S5-----	S23
Figure S6-----	S24
Figure S7-----	S24
Figure S8-----	S25
Figure S9-----	S25

General Remarks ^1H , ^{13}C and ^{31}P NMR spectra were recorded at 270, 68 and 109 MHz, respectively. The chemical shifts were measured from tetramethylsilane for ^1H NMR spectra and CDCl_3 (77 ppm) for ^{13}C NMR spectra and 85% phosphoric acid (0 ppm) for ^{31}P NMR spectra. Column chromatography was performed with silica gel C-200 purchased from Wako Co. Ltd., and a minipump for a goldfish bowl was conveniently used to attain sufficient pressure for rapid chromatographic separation. Anion-exchange HPLC was done on a Waters Alliance system with a Waters 3D UV detector and a Gen-PakTM FAX column (Waters, 4.6 x 100 mm). A linear gradient (10-60%) of Solvent I (1 M NaCl in 25 mM phosphate buffer (pH 6.0)) in solvent II (25 mM phosphate buffer (pH 6.0)) was used at 50 °C at a flow rate of 1.0 mL/min for 45 min. ESI mass was performed by use of MarinerTM (PerSeptive Biosystems Inc.). MALDI-TOF mass was performed by use of Bruker Daltonics [Matrix: 3-hydroxypicolinic acid (100mg/ml) in H_2O -diammoniumhydrogen citrate (100 mg/ml) in H_2O (10:1, v/v)]. Highly cross-linked polystyrene was purchased from ABI.




Scheme S1. Synthesis of phosphoramidite unit 1.

Synthesis of compound 7. 1,3,4-Triazole (1.09 g, 15.8 mmol) was suspended in dry CH_3CN (5 mL). To the solution was added slowly phosphoryl chloride (301 mg, 1.97 mmol) at 0 °C. After the mixture was stirred at 0 °C for 10 min, Et_3N (1.59 g, 15.8 mmol) was added to the mixture. After being stirred at 0 °C for 30 min, the dry CH_3CN

(5 mL) solution of s²T phosphoramidite unit **5** (500 mg, 0.66 mmol) was added to the mixture. After the mixture was stirred at room temperature for 3 h, the mixture was partitioned between CH₂Cl₂ (100 mL) and saturated brine (100 mL). The organic phase was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was treated with pyridine – 28% conc NH₃ aq (4:1, v/v, 125 mL) at room temperature for 2 h. The mixture was evaporated under reduced pressure. The residue was chromatographed on a column of NH-silica gel (20 g) with hexane- CHCl₃ (30:70–0:100, v/v) to give **2**. (462 mg, 93%) ¹H NMR (CDCl₃) δ 1.02-1.16 (m, 12H), 1.39, 1.44 (2s, 3H), 2.25-2.37 (m, 1H), 2.40, 2.63 (2t, 2H, *J* = 6.0 Hz), 2.77-2.93 (m, 1H), 3.31-3.36 (m, 1H), 3.50-3.60 (m, 3H), 3.63-3.65 (m, 1H), 3.79 (s, 6H), 4.15 (brs, 1H), 4.58-4.70 (m, 1H), 5.27 (brs, 1H), 6.80-6.85 (m, 4H), 7.03, 7.09 (2t, 1H, , *J* = 6.0 Hz), 7.22-7.29 (m, 7H), 7.40 (t, 2H, *J* = 7.3 Hz), 8.02, 8.08 (2s, 1H), 9.16 (brs, 1H). ¹³C NMR (CDCl₃) δ 12.6, 16.2, 24.5, 40.6, 40.9, 55.2, 58.3, 61.9, 62.5, 71.6, 72.6, 85.4, 86.8, 90.1, 106.5, 113.1, 117.5, 127.1, 127.9, 128.2, 130.2, 135.3, 138.9, 144.2, 158.7, 160.5, 178.4. ³¹P NMR (CDCl₃) δ 149.6, 150.5 HRMS (ESI) calcd for [C₄₀H₅₀N₅O₆PS+H]⁺ 760.3298, found 760.3285.

Synthesis of phosphoramidite unit 1. To the dry THF solution (5mL) of the 2'-deoxy-5-methyl-2-thiocytyne 3'-*O*-phosphoramidite derivative **7** (385 mg, 0.52 mmol) was added *N*-ethyldiisopropylamine (378 μL, 1.24 mmol) and benzoylchloride (145 μL, 0.83 mmol). After being stirred at room temperature for 1.5 h, the mixture was diluted with CHCl₃ (50 mL), and the mixture was washed three times with saturated NaHCO₃. The organic layer was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel (5 g) with 1% hexane-CHCl₃ (80:20–60:40, v/v) containing 1% triethylamine. The fractions were collected, evaporated under reduced pressure, and finally evaporated by repeated coevaporation three times each with toluene and CHCl₃ to remove the last traces of

triethylamine to give **1** (210 mg, 47%) (462 mg, 93%) ^1H NMR (CDCl_3) δ 1.06-1.19 (m, 12H), 1.61, 1.63 (2s, 3H), 2.35-2.40 (m, 1H), 2.43, 2.63 (2t, 2H, $J = 6.5$ Hz), 2.74-2.92 (m, 1H), 3.37-3.41 (m, 1H), 3.56-3.67 (m, 4H), 3.77-3.83 (m, 7H), 4.20, 4.24 (2s, 1H), 4.63-4.67 (m, 1H), 6.85-6.95 (m, 5H), 7.15-7.18 (m, 1H), 7.24-7.34 (m, 8H), 7.41-7.44 (m, 4H), 7.52 (t, 1H, $J = 7.3$ Hz), 8.07, 8.11 (2s, 1H), 7.29 (d, 2H, $J = 7.5$ Hz). ^{13}C NMR (CDCl_3) δ 13.0, 20.1, 20.2, 23.4, 24.5, 40.1, 43.1, 43.2, 43.3, 55.2, 55.25, 55.28, 58.0, 58.2, 62.1, 62.4, 77.2, 86.0, 86.9, 90.1, 90.2, 113.2, 113.3, 117.2, 117.3, 117.5, 127.2, 128.0, 128.1, 128.2, 128.8, 129.1, 129.8, 130.07, 130.12, 130.2, 132.5, 135.2, 136.9, 144.1, 156.1, 158.7. ^{31}P NMR (CDCl_3) δ 149.6, 150.2 HRMS (ESI) calcd for $[\text{C}_{47}\text{H}_{54}\text{N}_5\text{O}_7\text{PS}+\text{H}]^+$ 864.3554, found 864.3550.



Scheme S2. Synthesis of phosphoramidite units 2 and 3.

Synthesis of compound 11.

Compound **8** (25.8 g, 100 mmol) was rendered anhydrous by repeated coevaporation with dry pyridine and finally dissolved in dry pyridine (500 mL). 1,3-Dichloro-1,1,3,3-tetraisopropyl-1,3-disiloxane (34.4 mL, 120 mmol) was added, and the mixture was stirred at room temperature for 3 h. The mixture was quenched by addition of MeOH. The mixture was partitioned between CHCl_3 and saturated brine. The organic phase was collected, dried over Na_2SO_4 , filtered, and evaporated under reduced pressure. The residue was purified by chromatography with CHCl_3 -MeOH to afford compound **9**. Subsequently, the compound **9** was dissolved in CH_2Cl_2 (500 mL). Tetrabutylammonium bromide (12.9 g, 40 mmol), 2,4,6-

triisopropylbenzenesulfonylchloride (39.4 g, 130 mmol), and 0.2 M Na₂CO₃ aq. (1 L) were added. After being stirred at room temperature for 3 h, the mixture was partitioned between CH₂Cl₂ and Na₂CO₃ aq. The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was rendered anhydrous by repeated coevaporation with dry pyridine. The residue was further coevaporated with dry toluene and finally dissolved in dry CH₃CN (600 mL). 2,6-dimethylphenol (12.2 g, 100 mmol), triethylamine (41.9 mL, 300 mmol), and 1,4-diazabicyclo[2.2.2]octane (39.4 g, 130 mmol) were added. After being stirred at room temperature for 1 h, the mixture was partitioned between CHCl₃ and saturated brine. The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by chromatography with hexane-CHCl₃ and CHCl₃-MeOH to afford the deprotected compound **10** (40.2 g, 66.4 mmol).

Compound **10** (40.2 g, 66.4 mmol) was rendered anhydrous by repeated coevaporation with dry pyridine. The residue was further coevaporated with dry toluene and finally dissolved in dry DMF (600 mL). CH₃I (22 mL, 332 mmol) and NaH (3.3 g, 133 mmol) were added, and the mixture was stirred at room temperature for 20 min. The mixture was quenched by addition of acetic acid and diluted with ethyl acetate. The ethyl acetate solution was washed twice with saturated brine. The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by chromatography with hexane-ethyl acetate to afford **6**. (28.3 g, 46%): ¹H NMR (CDCl₃) δ 0.99-1.13 (m, 28H), 2.10 (s, 6H), 2.15 (s, 3H), 3.68 (s, 3H), 3.82 (d, 1H, *J* = 3.5 Hz), 3.98 (d, 1H, *J* = 14 Hz), 4.15-4.21 (m, 2H), 4.28 (d, 1H, *J* = 14 Hz), 5.75 (s, 1H), 7.03 (s, 3H), 3.96-4.00 (m, 2H), 4.12-4.27 (m, 3H), 6.19 (s, 1H), 6.98 (s, 3H), 8.21 (s, 1H); ¹³C NMR (CDCl₃) δ 12.6, 12.9, 14.1, 13.7, 16.7, 17.1, 17.2, 17.3, 17.6, 17.7, 59.4, 59.7, 68.2, 77.6, 81.9, 83.5, 89.9, 103.6, 125.9, 128.8, 128.9, 130.0, 130.3, 140.9, 149.7, 155.6, 169.9. HRMS (ESI) calcd for [C₃₁H₅₀N₂O₇Si₂+H]⁺ 619.3229, found 619.3213.

Synthesis of compound 12. Compound **11** (11 g, 17.7 mmol) was rendered anhydrous by repeated coevaporation with dry pyridine. The residue was further coevaporated with dry toluene and finally dissolved in dry toluene (200 mL). Phosphorus pentasulfide (10.3 g, 23 mmol) and K₂CO₃ (14.8 g, 106 mmol) were added. The resulting mixture

was refluxed for 20 min and then cooled to room temperature. The mixture was partitioned between CHCl_3 and saturated brine. The organic phase was collected, dried over Na_2SO_4 , filtered, and evaporated under reduced pressure. The residue was purified by chromatography with hexanes-ethyl acetate to afford compound **6** (24.3 g, 38% yield):

^1H NMR (CDCl_3) δ 0.87-1.07 (m, 28H), 2.04 (s, 6H), 2.14 (s, 3H), 3.68 (s, 3H), 3.96-4.00 (m, 2H), 4.12-4.27 (m, 3H), 6.19 (s, 1H), 6.98 (s, 3H), 8.21 (s, 1H); ^{13}C NMR (CDCl_3) δ 12.4, 12.6, 12.7, 12.8, 13.0, 13.3, 13.5, 16.3, 16.5, 16.8, 16.9, 17.0, 17.1, 17.2, 17.4, 59.3, 60.3, 68.3, 68.3, 77.2, 82.2, 82.7, 94.1, 108.9, 125.5, 125.8, 129.3, 128.7, 129.9, 130.3, 142.4, 149.2, 164.1, 179.6. HRMS (ESI) calcd for $[\text{C}_{31}\text{H}_{50}\text{N}_2\text{O}_6\text{SSi}_2+\text{H}]^+$ 635.3001, found 635.3008.

Synthesis of compound 13. Compound **12** (4.3 g, 6.78 mmol) was rendered anhydrous by repeated coevaporation with dry pyridine. The residue was further coevaporated with dry toluene and finally dissolved in dry CH_3CN (30 mL). A solution of 1,1,3,3-tetramethylguanidine (2.5 mL, 20.3 mmol) and *syn-o*-nitrobenzaldoxime (2.4 g, 20.3 mmol) in CH_3CN (30 mL) was added. After being stirred at room temperature for 18 h, the mixture was partitioned between CHCl_3 and saturated brine. The combined organic extracts were dried over Na_2SO_4 , filtered, and concentrated in vacuo. The residue was purified by chromatography with hexane- CHCl_3 to afford the deprotected compound. The deprotected compound was rendered anhydrous by repeated coevaporation with dry pyridine. The residue was further coevaporated with dry toluene and finally dissolved in dry THF (100 mL). To the solution were added $\text{Et}_3\text{N}\cdot 3\text{HF}$ (4.4 mL, 27 mmol) and Et_3N (7.5 mL, 54 mmol). After being stirred at room temperature for 1 h, the mixture was concentrated in vacuo. The residue was purified by chromatography with CHCl_3 -MeOH to give compound **13** (1.6 g, 82%):

^1H NMR (DMSO) δ 1.80 (s, 3H), 3.44 (s, 3H), 3.60 (d, 1H, $J = 12$ Hz), 3.74 (d, 1H, $J = 12.5$ Hz), 3.78 (s, 1H), 3.87 (d, 1H, $J = 5.0$ Hz), 4.12 (s, 1H), 5.16 (brs, 1H), 5.35 (brs, 1H), 6.58 (s, 1H), 8.15 (s, 1H), 12.59 (brs, 1H); ^{13}C NMR (DMSO) δ 12.6, 58.5, 59.5, 67.8, 83.5, 84.6, 90.9, 115.0, 137.0, 160.6, 174.6. HRMS (ESI) calcd for $[\text{C}_{11}\text{H}_{16}\text{N}_2\text{O}_5\text{S}+\text{H}]^+$ 289.0853, found 289.0894.


Synthesis of compound 14. Compound **13** (1.6 g, 7.0 mmol) was rendered anhydrous by coevaporation three times with dry pyridine and finally dissolved in dry pyridine (70 mL). To the solution was added DMTr-Cl (2.9 g, 8.4 mmol). After being stirred at room temperature for 6 h, the mixture was partitioned between CHCl₃ (200 mL) and saturated brine (200 mL). The organic phase was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with CHCl₃-MeOH (100:0–97:3, v/v) containing 1% Et₃N to give compound **14**. (2.7g, 65%) ¹H NMR (CDCl₃) δ 1.30 (s, 3H), 3.49 (d, 1H, *J* = 11 Hz), 3.63 (d, 1H, *J* = 11 Hz), 3.79 (s, 3H) 3.81 (s, 6H), 3.99 (d, 1H, *J* = 4.5 Hz), 4.09 (d, 1H, *J* = 7.5 Hz), 4.55 (t, 1H, *J* = 6.3 Hz), 6.68 (s, 1H), 6.86 (d, 4H, *J* = 8.0 Hz), 7.28-7.44 (m, 9H), 7.93 (s, 1H), 10.21 (brs, 1H). ¹³C NMR (CDCl₃) δ 11.8, 55.1, 55.2, 60.0, 60.1, 61.4, 68.6, 83.2, 83.3, 83.9, 84.0, 86.8, 91.6, 91.7, 113.1, 113.2, 116.6, 123.7, 127.1, 128.0, 128.2, 130.0, 130.1, 135.1, 135.2, 136.1, 136.2, 136.3, 144.1, 149.5, 158.6, 158.7, 160.8, 174.0. HRMS (ESI) calcd for [C₃₂H₃₄N₂O₇S+Na]⁺ 613.1979, found 613.1985.

Synthesis of phosphoramidite unit 2. Compound **14** (2.7 g, 4.6 mmol) was rendered anhydrous by repeated coevaporation with dry CH₃CN (3ml x 3) and dissolved in dry CH₂Cl₂ (20 ml). To the mixture was added diisopropylamine (387 μL, 2.74 mmol), 2-cyanoethoxy[bis(*N,N*-diisopropylamino)]phosphine (2.18 mL, 6.7 mmol) and 1-*H*-tetrazole (192 mg, 2.74 mmol). After the mixture was stirred at room temperature for 4 h, water (5 ml) was added to the mixture. After being stirred at room temperature for 10 min, the mixture was partitioned between CHCl₃ (200 ml) and brine (200 ml). The organic phase was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with hexane-CHCl₃ (50:50–0:100, v/v) containing 1% Et₃N and then CHCl₃-MeOH (100:0–97:3, v/v) containing 1% Et₃N to give the fractions containing phosphoramidite unit **2**.

The fractions were collected and evaporated under reduced pressure. The residue was finally evaporated by repeated coevaporation three times each with toluene and CHCl_3 to remove the last traces of Et_3N to give phosphoramidite unit **2**. (3.6 g, 72%) ^1H NMR (CDCl_3) δ 1.00–1.26 (m, 15H) 2.38, 2.66 (2t, 2H, $J = 6.0$ Hz), 3.37–3.45 (m, 2H), 3.59–3.62 (m, 2H), 3.65, 3.68 (2s, 3H), 3.73–3.95 (m, 8H), 4.04–4.08 (m, 1H), 4.23–4.31 (m, 1H), 4.45–4.62 (m, 1H), 6.59–6.68 (m, 1H), 6.82–6.86 (m, 4H), 7.29–7.42 (m, 9H), 7.92, 7.98 (2s, 1H), 9.21 (brs, 1H); ^{13}C NMR (CDCl_3) δ 11.6, 24.5, 24.6, 43.2, 43.3, 55.2, 55.3, 92.4, 113.1, 113.2, 116.5, 116.6, 127.3, 128.0, 128.3, 128.5, 130.3, 130.3, 130.4, 135.1, 136.4, 144.0, 158.8; ^{31}P NMR (CDCl_3) 151.5, 151.6. HRMS (ESI) calcd for $[\text{C}_{41}\text{H}_{51}\text{N}_4\text{O}_8\text{PS}+\text{Na}]^+$ 813.3057, found 813.3035.

Synthesis of phosphoramidite unit 3. 1,3,4-Triazole (2.1 g, 30.4 mmol) was suspended in dry CH_3CN (10 mL). To the solution was added slowly phosphoryl chloride (343 μL , 1.97 mmol) at 0 °C. After the mixture was stirred at 0 °C for 10 min, Et_3N (4.2 mL, 30.4 mmol) was added to the mixture. After being stirred at 0 °C for 30 min, the dry CH_3CN (10 mL) solution of phosphoramidite unit **2** (1.0 g, 1.26 mmol) was added to the mixture. After the mixture was stirred at room temperature for 1 h, the mixture was partitioned between CH_2Cl_2 (100 mL) and saturated brine (100 mL). The organic phase was collected, dried over Na_2SO_4 , filtered, and evaporated under reduced pressure. The residue was treated with pyridine – 28% conc NH_3 aq (4:1, v/v, 20 mL) at room temperature for 30 min. The mixture was evaporated under reduced pressure. The residue was chromatographed on a column of NH-silica gel with hexane- CHCl_3 (30:70–0:100, v/v) to give compound **15** (880 mg). To the dry CH_2Cl_2 solution (15 mL) of the compound **15** (880 mg, 1.1 mmol) were added *N*-ethyldiisopropylamine (423 μL , 2.42 mmol) and benzoylchloride (140 μL , 1.21 mmol). After being stirred at room temperature for 2.5 h, the mixture was diluted with CHCl_3 (50 mL), and the mixture was washed three times with saturated NaHCO_3 . The organic layer was collected, dried over Na_2SO_4 , filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with 1% hexane- CHCl_3 (80:20–60:40, v/v) containing 1% triethylamine. The fractions were collected, evaporated under reduced pressure, and finally evaporated by repeated coevaporation three times each with

toluene and CHCl_3 to remove the last traces of triethylamine to give phosphoramidite unit **3** (770 mg, 78%). ^1H NMR (CDCl_3) δ 0.98–1.31 (m, 15H) 2.38, 2.64 (2t, 2H, J = 6.3 Hz), 3.37–3.44 (m, 2H), 3.57–3.90 (m, 10H), 4.06, 4.15 (2d, 1H, J = 4.0 Hz), 4.31, 4.37 (2d, 1H, J = 9.5 Hz), 4.53–4.58 (m, 1H), 6.41 (s, 1H, J = 4.0 Hz), 6.81–6.86 (m, 4H), 7.22–7.51 (m, 10H), 7.71 (d, 4H, J = 7.5 Hz), 8.66, 8.67 (2s, 1H); ^{13}C NMR (CDCl_3) δ 1.9, 13.5, 20.0, 20.1, 20.3, 20.4, 24.4, 24.5, 24.6, 24.7, 43.1, 43.2, 43.3, 55.2, 57.8, 58.0, 58.2, 60.1, 60.3, 60.4, 68.7, 68.9, 69.7, 69.8, 81.9, 83.1, 86.9, 94.6, 95.1, 113.2, 115.9, 116.4, 117.3, 117.4, 127.2, 127.3, 128.0, 128.5, 128.6, 128.8, 129.1, 130.4, 133.1, 133.8, 135.0, 144.0, 144.1, 145.4, 153.6, 158.8, 161.0, 161.1, 171.7, 171.8, 178.5; ^{31}P NMR (CDCl_3) 151.5, 151.6. HRMS (ESI) calcd for $[\text{C}_{41}\text{H}_{51}\text{N}_4\text{O}_8\text{PS}+\text{Na}]^+$ 916.3479, found 916.3462.



Scheme S3. Synthesis of phosphoramidite unit 4.

Synthesis of compound 17. Bromine (6.8 g, 42 mmol) was suspended in 2 M sodium acetate buffer (pH 4.3, 50 mL). After being stirred at room temperature for 1 h, the solution was slowly added to 2 M sodium acetate buffer (pH 4.3, 140 mL) of 2'-O-

methyladenosine **16** (10 g, 35.5 mmol). After being stirred at room temperature for 6 h, 5% sodium thiosulfate (100 mL) and 2 M sodium hydroxide (200 mL) was added to the mixture. The resulting precipitates were collected by filtration with water to give the compound **17** (7.1 g, 56%). ¹H NMR (DMSO) δ 3.31 (s, 3H, 2'-O-Me), 3.51-3.55 (m, 1H), 3.67-3.69 (m, 1H), 4.00 (d, 1H, *J* = 2.5 Hz), 4.42 (d, 1H, *J* = 2.5 Hz), 4.86 (dd, 1H, *J* = 5.3 Hz, 6.8 Hz), 5.34 (d, 1H, *J* = 5.0 Hz), 5.47 (dd, 1H, *J* = 3.8 Hz, 8.3 Hz), 5.92 (d, 1H, *J* = 6.5 Hz), 7.58 (bs, 2H, 6-NH₂), 8.14 (s, 1H). ¹³C NMR (DMSO) δ 22.9, 58.2, 62.6, 69.6, 80.7, 88.0, 89.2, 120.3, 124.6, 127.7, 136.9, 150.3, 150.5, 153.3, 155.9. HRMS (ESI) calcd for [C₁₁H₁₄BrN₅O₄+H]⁺ 360.0307, found 360.0283.

Synthesis of compound 18. Compound **17** (5 g, 13.9 mmol) was rendered anhydrous by coevaporation three times with dry pyridine and finally dissolved in DMF (140 mL). To the solution were added K₂CO₃ (6.7 g, 48.7 mmol) and 2-(trimethylsilyl)ethanthiol (2.7 ml, 16.7 mmol). After being stirred at 50 °C for 18 h, the mixture was partitioned between AcOEt (500 mL) and saturated brine (300 mL). The organic phase was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with CHCl₃-MeOH (100:0–95:5, v/v) to give **18**. (4.48 g, 78%) ¹H NMR (DMSO) δ 0.05 (s, 9H) 0.86-0.90 (m, 2H), 0.99-1.02 (m, 2H), 3.34 (s, 3H, OMe) 3.51-3.56 (m, 1H), 3.66-3.68 (m, 1H), 3.99 (bs, 1H), 4.38 (bs, 1H), 4.77 (dd, 1H, *J* = 5.3 Hz, 6.8 Hz), 5.32 (bs, 1H), 5.67 (dd, 1H, *J* = 3.3 Hz, 8.3 Hz), 5.87 (d, 1H, *J* = 6.5 Hz), 7.30 (s, 2H), 8.07 (s, 1H). ¹³C NMR (DMSO) δ -1.0, 17.3, 17.5, 30.1, 34.5, 36.4, 58.1, 62.8, 69.7, 75.7, 80.9, 87.6, 87.9, 120.4, 149.2, 150.9, 152.2, 155.3, 163.0. HRMS (ESI) calcd for [C₁₆H₂₇N₅O₄SSi+H]⁺ 414.1631, found 414.1603.

Synthesis of compound 19. Compound **18** (1.5 g, 3.6 mmol) was rendered anhydrous by coevaporation three times with dry pyridine and finally dissolved in dry pyridine (36 mL). To the solution was added trimethylsilyl chloride (1.6 mL, 12.6


mmol). After being stirred at room temperature for 6 h, benzoyl chloride was added to the mixture. After being stirred at room temperature for 1 day, to the solution was added 28% ammonium hydroxide. After being stirred at room temperature for 10 min, the mixture was evaporated under reduced pressure. The mixture was partitioned between CHCl_3 (200 mL) and saturated brine (200 mL). The organic phase was collected, dried over Na_2SO_4 , filtered, and evaporated under reduced pressure. The residue was dissolved in dry THF (20 mL) and treated with Et_3N -3HF (1.4 mL, 8.7 mmol) for 30 min. The mixture was partitioned between CHCl_3 (500 mL) and saturated brine (300 mL). The organic phase was collected, dried over Na_2SO_4 , filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with CHCl_3 -MeOH (100:0–95:5, v/v) to give **19**. (950 mg, 51%) ^1H NMR (DMSO) δ -0.08 (s, 9H) 1.13-1.16 (m, 2H), 3.30-3.27 (m, 5H), 3.55-3.57 (m, 1H), 3.69-3.71 (m, 1H), 3.98 (brs, 1H), 4.43 (brs, 1H), 4.89 (t, 1H, $J = 5.8$ Hz), 5.10 (brs, 1H), 5.37 (d, 1H, $J = 6.0$ Hz), 5.85 (d, 1H, $J = 6.5$ Hz), 7.54 (t, 1H, $J = 7.8$ Hz), 7.63 (t, 1H, $J = 7.3$ Hz), 8.04 (d, 1H, $J = 7.5$ Hz), 8.65 (s, 1H), 11.11 (brs, 1H). ^{13}C NMR (CDCl_3) δ -1.6, 17.7, 29.7, 58.9, 63.4, 70.7, 88.2, 88.4, 124.5, 128.0, 129.1, 133.0, 134.0, 147.6, 150.7, 152.7, 155.4, 164.6. HRMS (ESI) calcd for $[\text{C}_{23}\text{H}_{31}\text{N}_5\text{O}_5\text{SSi}+\text{H}]^+$ 518.1893, found 518.1918.

Synthesis of compound 20. Compound **19** (950 mg, 1.8 mmol) was rendered anhydrous by coevaporation three times with dry pyridine and finally dissolved in dry pyridine (18 mL). To the solution was added DMTr-Cl (740 mg, 2.2 mmol). After being stirred at room temperature for 2 h, the mixture was partitioned between CHCl_3 (200 mL) and saturated brine (200 mL). The organic phase was collected, dried over Na_2SO_4 , filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with CHCl_3 -MeOH (100:0–97:3, v/v) containing 1% Et_3N to give **20**. (1.4 g, 78%) ^1H NMR (CDCl_3) δ 0.09 (s, 9H), 1.15 (t, 2H, $J = 9.0$ Hz), 3.31-3.49 (m, 5H) 3.75 (s, 6H), 4.23 (d, 1H, $J = 5.0$ Hz), 4.76 (d, 1H, $J = 4.5$ Hz), 5.04 (t, 1H, $J =$

4.8 Hz), 6.04 (d, 1H, $J = 4.5$ Hz), 6.77 (dd, 4H, $J = 6.3$ Hz, 8.3 Hz), 7.17-7.56 (m, 13H), 8.01 (d, 2H, $J = 7.5$ Hz), 8.55 (s, 1H), 9.26 (s, 1H). ^{13}C NMR (CDCl_3) δ -1.5, 17.8, 29.6, 55.4, 58.9, 63.6, 70.3, 80.8, 84.4, 86.4, 87.4, 113.3, 123.9, 127.0, 127.9, 128.0, 128.5, 129.1, 130.4, 132.7, 134.2, 136.2, 136.3, 145.1, 147.1, 151.3, 153.7, 155.4, 158.6, 158.7, 164.8. HRMS (ESI) calcd for $[\text{C}_{44}\text{H}_{49}\text{N}_5\text{O}_7\text{SSi}+\text{H}]^+$ 820.3200, found 820.3191.

Synthesis of phosphoramidite unit 4. Compound **20** (1.0 g, 1.2 mmol) was rendered anhydrous by repeated coevaporation with dry CH_3CN (3ml x 3) and dissolved in dry CH_2Cl_2 (20 ml). To the mixture was added diisopropylamine (100 μl , 0.73 mmol), 2-cyanoethoxy[bis(*N,N*-diisopropylamino)]phosphine (470 μl , 1.5 mmol) and 1-*H*-tetrazole (50 mg, 0.73 mmol). After the mixture was stirred at room temperature for 4 h, water (5 ml) was added to the mixture. After being stirred at room temperature for 10 min, the mixture was partitioned between CHCl_3 (100 ml) and brine (100 ml). The organic phase was collected, dried over Na_2SO_4 , filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with hexane- CHCl_3 (50:50–0:100, v/v) containing 1% Et_3N and then CHCl_3 -MeOH (100:0–97:3, v/v) containing 1% Et_3N to give the fractions containing phosphoramidite unit **4**. The fractions were collected and evaporated under reduced pressure. The residue was finally evaporated by repeated coevaporation three times each with toluene and CHCl_3 to remove the last traces of Et_3N to give phosphoramidite unit **4**. (831 mg, 68%) ^1H NMR (CDCl_3) δ 0.02, 0.11 (2s, 9H), 1.12-1.26 (m, 14H), 2.42-2.71 (m, 2H), 3.31-3.68 (m, 10H), 3.78-7.9 (m, 6H), 3.92-3.98 (m, 1H), 4.34-4.39 (m, 1H), 4.77-4.93 (m, 1H), 5.17-5.27 (m, 1H), 5.97-5.98 (m, 1H), 6.75-6.80 (m, 4H), 7.20-7.23 (m, 3H), 7.27-7.31 (m, 6H), 7.31-7.42 (m, 2H), 7.54-7.56 (m, 2H), 7.62-7.62 (m, 1H), 8.01 (d, 2H, $J = 7.0$ Hz), 8.51, 8.55 (2s, 1H), 8.86 (s, 1H); ^{13}C NMR (CDCl_3) δ -1.5, 17.8, 20.3, 20.4, 20.6, 24.8, 29.5, 43.3, 43.4, 43.5, 43.6, 55.4, 58.4, 58.6, 58.8, 59.2, 59.4, 62.9, 63.3, 70.6, 70.8,

71.5, 71.6, 79.7, 79.9, 83.8, 86.4, 87.2, 87.3, 113.2, 117.7, 118.0, 123.7, 126.9, 127.9, 128.4, 128.5, 129.1, 130.3, 130.3, 132.8, 134.3, 136.0, 136.2, 144.9, 145.0, 146.9, 151.1, 151.2, 153.5, 155.7, 155.8, 158.6, 164.5; ^{31}P NMR (CDCl_3) 150.9, 152.1. HRMS (ESI) calcd for $[\text{C}_{53}\text{H}_{66}\text{N}_7\text{O}_8\text{PSSi}+\text{H}]^+$ 1020.4279, found 1020.4197.



Scheme S4. Synthesis of phosphoramidite unit 5.

Synthesis of compound 22. Compound **18** (1.2 g, 2.9 mmol) was rendered anhydrous by coevaporation three times with dry pyridine and finally dissolved in AcOH-H₂O (7:1, v/v, 29 mL). To the solution were added NaNO₂ (1 g, 14.5 mmol) and 2-(trimethylsilyl)ethanthiol (2.7 ml, 16.7 mmol). After being stirred at room temperature for 18 h, the mixture was partitioned between CHCl₃ (200 mL) and saturated brine (200 mL). The organic phase was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The resulting residue was rendered anhydrous by coevaporation three times with dry pyridine and finally dissolved in dry pyridine (29 mL). To the solution was added DMTr-Cl (1.2 g, 3.5 mmol). After being stirred at room temperature for 2 h, the mixture was partitioned between CHCl₃ (200 mL) and saturated brine (200 mL). The organic phase was collected, dried over Na₂SO₄, filtered, and evaporated under reduced pressure. The residue was chromatographed on a column

of silica gel with CHCl_3 -MeOH (100:0–97:3, v/v) containing 1% Et_3N to give **20**. (1.3 g, 62%) ^1H NMR (CDCl_3) δ 0.09 (s, 9H, TMS), 1.00-1.03 (m, 2H), 3.40-3.47 (m, 7H), 3.74-3.77 (m, 6H) .415 (m, 1H), 4.65 (dd, 1H, $J = 5.5$ Hz, $J = 11.5$ Hz), 4.79 (t, 1'H, $J = 5.0$ Hz), 6.00 (d, 1H, $J = 4.5$ Hz), 6.77 (d, 4H, $J = 8.0$ Hz), 7.17-7.45 (m, 9H), 7.73 (s, 1H), 12.6 (s, 1H). ^{13}C NMR (CDCl_3) δ -1.5, 16.9, 29.6, 55.4, 58.9, 63.8, 70.4, 81.2, 84.3, 86.5, 87.6, 113.2, 125.6, 127.0, 127.9, 128.5, 130.4, 136.2, 143.3, 145.1, 150.6, 151.1, 158.6, 158.7. HRMS (ESI) calcd for $[\text{C}_{37}\text{H}_{44}\text{N}_4\text{O}_7\text{SSi}+\text{H}]^+$ 717.2778, found 717.2774.

Synthesis of phosphoramidite unit 5. Compound **22** (1.0 g, 1.4 mmol) was rendered anhydrous by repeated coevaporation with dry CH_3CN (3ml x 3) and dissolved in dry CH_2Cl_2 (14 ml). To the mixture was added diisopropylethylamine (803 μl , 4.6 mmol) and 2-cyanoethoxy(*N,N*-diisopropylamino)chlorophosphine (686 μl , 3.1 mmol). After the mixture was stirred at room temperature for 1.5 h, water (5 ml) was added to the mixture. After being stirred at room temperature for 10 min, the mixture was partitioned between CHCl_3 (100 ml) and brine (100 ml). The organic phase was collected, dried over Na_2SO_4 , filtered, and evaporated under reduced pressure. The residue was chromatographed on a column of silica gel with hexane- CHCl_3 (50:50–0:100, v/v) containing 1% Et_3N and then CHCl_3 -MeOH (100:0–97:3, v/v) containing 1% Et_3N to give the fractions containing **21**. The fractions were collected and evaporated under reduced pressure. The residue was finally evaporated by repeated coevaporation three times each with toluene and CHCl_3 to remove the last traces of Et_3N to give phosphoramidite unit **5**. (808 mg, 63%) ^1H NMR (CDCl_3) δ 0.06, 0.07 (2s, 9H), 0.99-1.24 (m, 14H), 2.40-2.70 (m, 2H), 3.33-3.67 (m, 10H), 3.74, 3.75 (2s, 6H), 3.92-3.98 (m, 1H), 4.30-4.36 (m, 1H), 4.66-4.84 (m, 1H), 4.87-5.04 (m, 1H), 5.99 (d, 1H, $J = 6.0$ Hz), 6.74-6.80 (m, 4H), 7.17-7.44 (m, 9H), 7.77, 7.80 (2s, 1H), 8.86 (s, 1H), 13.50 (brs, 1H); ^{13}C NMR (CDCl_3) δ -1.4, 16.8, 20.5, 20.6, 24.8, 24.9, 29.7, 43.4, 43.5,

43.6, 43.7, 55.3, 58.4, 58.8, 59.3, 59.4, 86.5, 86.6, 87.4, 113.2, 118.0, 125.6, 127.0, 127.9, 128.5, 128.6, 130.3, 130.4, 136.1, 145.0, 150.7, 151.4, 151.5, 158.7; ^{31}P NMR (CDCl_3) 150.7, 152.0. HRMS (ESI) calcd for $[\text{C}_{46}\text{H}_{61}\text{N}_6\text{O}_8\text{PSSi}+\text{H}]^+$ 917.3857, found 917.3872.

Synthesis of TFOs 2-12 and 15-17.

(For TFO containing $s^8\text{A}$ and $s^8\text{I}$) The synthesis of TFOs was carried out on a T-loaded CPG resin (1 μmol scale) in ABI 392 DNA synthesizer. (Activator: 0.25 M solution of 5-benzylthio-1H-tetrazole, Oxidizer: 0.02 M solution of I_2) The fully protected oligomer after chain elongation was deprotected and released from the resin by treatment with a 28% ammonia solution at 50 $^\circ\text{C}$ for 8 h. The mixture was evaporated and the resulting residue was rendered anhydrous by repeated coevaporation with dry CH_3CN . After the coevaporation, the oligomer was dissolved in 1 M Tetrabutylammonium fluoride/THF and the mixture was stirred at room temperature for 2 h. The crude mixture was purified by Sep-Pak C18 cartridge and anion-exchange HPLC to give TFO.

(For TFO without $s^8\text{A}$ and $s^8\text{I}$) The synthesis of TFOs was carried out on a T-loaded CPG resin (1 μmol scale) in ABI 392 DNA synthesizer. (Activator: 0.25 M solution of 5-benzylthio-1H-tetrazole, Oxidizer: 0.02 M solution of I_2) The fully protected oligomer after chain elongation was deprotected and released from the resin by treatment with a 28% ammonia solution at 50 $^\circ\text{C}$ for 8 h. The crude mixture was purified by Sep-Pak C18 cartridge and anion-exchange HPLC.

TFO 2: TTTCTTm 5 s 2 CTTCTT, Yield 78%, MALDI-TOF Mass ($\text{M}+\text{H}$) calcd for $[\text{C}_{118}\text{H}_{156}\text{N}_{27}\text{O}_{76}\text{P}_{11}\text{S} + \text{H}]^+$ 3572.6, found 3569.4

TFO 3: $\text{TTTCs}^2\text{Ts}^2\text{TCs}^2\text{Ts}^2\text{TCTT}$, Yield 68%, MALDI-TOF Mass (M+H) calcd for $[\text{C}_{117}\text{H}_{154}\text{N}_{27}\text{O}_{75}\text{P}_{11}\text{S}_4 + \text{H}]^+$ 3606.5, found 3609.7

TFO 4: $\text{TTTCs}^2\text{Ts}^2\text{Tm}^5\text{s}^2\text{Cs}^2\text{Ts}^2\text{TCTT}$, Yield 70%, MALDI-TOF Mass (M+H) calcd for $[\text{C}_{118}\text{H}_{156}\text{N}_{27}\text{O}_{74}\text{P}_{11}\text{S}_5 + \text{H}]^+$ 3636.5, found 3638.5

TFO 5: $\text{TTTm}^5\text{s}^2\text{Cs}^2\text{Ts}^2\text{Tm}^5\text{s}^2\text{Cs}^2\text{Ts}^2\text{Tm}^5\text{s}^2\text{CTT}$, Yield 21%, MALDI-TOF Mass (M+H) calcd for $[\text{C}_{120}\text{H}_{160}\text{N}_{27}\text{O}_{72}\text{P}_{11}\text{S}_7 + \text{H}]^+$ 3696.5, found 3695.2

TFO 6: $\text{TTTs}^2\text{Ts}^2\text{TCCCCs}^2\text{Ts}^2\text{TTT}$, Yield 61%, MALDI-TOF Mass (M+H) calcd for $[\text{C}_{126}\text{H}_{165}\text{N}_{30}\text{O}_{81}\text{P}_{12}\text{S}_4 + \text{H}]^+$ 3895.6, found 3898.2

TFO 7: $\text{TTTs}^2\text{Ts}^2\text{Tm}^5\text{s}^2\text{Cm}^5\text{s}^2\text{Cm}^5\text{s}^2\text{Cm}^5\text{s}^2\text{Cs}^2\text{Ts}^2\text{TTT}$, Yield 54%, MALDI-TOF Mass (M+H) calcd for $[\text{C}_{130}\text{H}_{173}\text{N}_{30}\text{O}_{77}\text{P}_{12}\text{S}_8 + \text{H}]^+$ 4015.5, found 4013.7

TFO 8: $\text{TTTs}^2\text{Ts}^2\text{Ts}^8\text{A}^8\text{A}^8\text{s}^8\text{A}^8\text{s}^2\text{Ts}^2\text{TTT}$, Yield 34%, MALDI-TOF Mass (M+H) calcd for $[\text{C}_{130}\text{H}_{166}\text{N}_{38}\text{O}_{77}\text{P}_{12}\text{S}_8 + \text{H}]^+$ 4119.5, found 4122.1.

TFO 9: $\text{s}^2\text{Ts}^2\text{Ts}^2\text{Ts}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{T}$, Yield 24%, MALDI-TOF Mass (M+H) calcd for $[\text{C}_{150}\text{H}_{301}\text{N}_{35}\text{O}_{84}\text{P}_{14}\text{S}_{14} + \text{H}]^+$ 4718.5, found 4719.2.

TFO 10: $2\text{-OMe}[\text{s}^2\text{Ts}^2\text{Ts}^2\text{Ts}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{T}]$, Yield 5%, MALDI-TOF Mass (M+H) calcd for $[\text{C}_{164}\text{H}_{229}\text{N}_{35}\text{O}_{98}\text{P}_{14}\text{S}_{14} + \text{H}]^+$ 5138.7, found 5139.9.

TFO 11: $2\text{-OMe}[\text{s}^2\text{Ts}^2\text{Ts}^2\text{Ts}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{Tm}^5\text{s}^2\text{C}^2\text{T}]$, Yield 14%, MALDI-TOF Mass (M+H) calcd for $[\text{C}_{164}\text{H}_{229}\text{N}_{35}\text{O}_{98}\text{P}_{14}\text{S}_{14} + \text{H}]^+$ 5138.7, found 5264.3.

TFO 12: 2-OMe[s²Ts²Ts²Ts²T s⁸I s²T s⁸I s²T s⁸I s²T s⁸I s²T s⁸I]T, Yield 18%, MALDI-TOF Mass (M+H) calcd for [C₁₆₄H₂₀₁N₆₃O₉₈P₁₄S₁₄ + H]⁺ 5502.5, found 5499.4.

TFO 15: 2-OMe[s⁸A s⁸A s⁸A s²T s²T s²T s²T s²T s⁸A s²T]T, Yield 16%, MALDI-TOF Mass (M+H) calcd for [C₁₂₀H₁₆₀N₃₄O₇₁P₁₀S₁₀ + H]⁺ 3843.5, found 384.

TFO 16: TTTs²Ts²Ts²Tm⁵s²Cs²Ts²Ts²TTT, Yield 29%, MALDI-TOF Mass (M+H) calcd for [C₁₂₀H₁₅₈N₂₅O₇₄P₁₁S₇ + H]⁺ 3698.5, found 3699.2

TFO 17: TTTs²Ts²Ts²TCs²Ts²Ts²TTT, Yield 58%, MALDI-TOF Mass (M+H) calcd for [C₁₁₉H₁₅₆N₂₅O₇₅P₁₁S₆ + H]⁺ 3668.5, found 3668.4

Table S1. Selectivity of TFO 3-4 containing C and m⁵s²C at pH 7.0.

TFO 3-4 5'-T T T C s²T s²T X s²T s²T C T T
X = C (TFO 3), m⁵s²C (TFO 4)
HP 1, 5-7 5'-G A A A G A A Y A A G A A A C T T
3'-C T T T C T T Y' T T C T T T G T T
Y-Y' = G-C (HP 1), C-G (HP 5), A-T (HP 6), T-A (HP 7)

entry	oligonucleotides	<i>T_m</i> (°C) ^[a]	Δ <i>T_m</i> (°C)
1	TFO 3 – HP 1	37	-
2	TFO 3 – HP 5	15	22 ^[b]
3	TFO 3 – HP 6	9	28 ^[b]
4	TFO 3 – HP 7	10	27 ^[b]
5	TFO 4 – HP 1	44	-
6	TFO 4 – HP 5	16	28 ^[c]
7	TFO 4 – HP 6	12	32 ^[c]
8	TFO 4 – HP 7	11	33 ^[c]

[a] The T_m values are accurate within ± 0.5 °C. The T_m measurements were carried out in a buffer containing 10 mM sodium cacodylate buffer (pH 7.0), 500 mM NaCl, 10 mM $MgCl_2$, and 2 μM triplex. [b] ΔT_m is the difference in the T_m value between the matched triplex (entry 1) and the mismatched triplexes (entries 2–4). [c] ΔT_m is the difference in the T_m value between the matched triplex (entry 5) and the mismatched triplexes (entries 6–8).





Figure S1. T_m values for DNA triplexes formed between TFO **16** and HP **8** at varied pH conditions (pH 6.0–7.2) The T_m values are accurate within ± 0.5 °C. The T_m measurements were carried out in a buffer containing 10 mM sodium cacodylate buffer (pH 6.0–7.2), 500 mM NaCl, 10 mM MgCl₂, and 2 μ M triplex.




Figure S2. T_m values for DNA triplexes formed between TFO **17** and HP **8** at varied pH conditions (pH 5.0–7.2). The T_m values are accurate within ± 0.5 °C. The T_m measurements were carried out in a buffer containing 10 mM sodium cacodylate buffer (pH 5.0–7.2), 500 mM NaCl, 10 mM $MgCl_2$, and 2 μM triplex.




Figure S3. Computer modelling of a DNA triplexes for distance between the C1' atoms in the neighboring mononucleotide units a) C⁺-G-C, b) s⁸A-G-C.




Figure S4. Electrophoretic mobility shift assay of the triplex formed between TFO 13 and HP 4 (40 nM) on 10% nondenaturing polyacrylamide gel at pH 7.0. Indicated concentrations of TFO 13 were incubated with HP 4 for 2 h at 37 °C.




Figure S5. Electrophoretic mobility shift assay of the triplex formed between TFO 14 and HP 4 (40 nM) on 10% nondenaturing polyacrylamide gel at pH 7.0. Indicated concentrations of TFO 14 were incubated with HP 4 for 2 h at 37 °C.




Figure S6. Melting curve of the triplex formed between .TFO 9 and HP 3 by UV analysis at 260 nm.




Figure S7. Melting curve of the triplex formed between .TFO 10 and HP 3 by UV analysis at 290 nm.




Figure S8. Melting curve of the triplex formed between .TFO 11 and HP 3 by UV analysis at 290 nm.




Figure S9. Melting curve of the triplex formed between .TFO 12 and HP 3 by UV analysis at 290 nm.